Introduction

Non-small cell lung cancer (NSCLC) continues to pose a significant health burden globally and in India, necessitating the exploration of novel therapeutic avenues. Recent scientific focus on natural flavonoids, specifically Baicalein for NSCLC, has revealed promising results due to its potential to modulate the tumor microenvironment (TME). By integrating single-cell and spatial transcriptomics, researchers have now mapped a high-resolution atlas of baicalein-responsive genes, providing a roadmap for future targeted therapies.

The study utilized an advanced methodology combining network pharmacology, single-cell RNA sequencing, and machine learning to resolve 21 distinct cell populations. Furthermore, consensus clustering identified three molecular subtypes, distinguishing between "immune-cold" phenotypes with metabolic upregulation and "immune-hot" phenotypes. This granular view allows clinicians to understand how natural compounds like baicalein interact with specific cellular niches in the lung.

The Diagnostic Value of Baicalein for NSCLC

Using machine learning and SHAP analysis, researchers identified a robust 10-gene signature (TOP2A, CDH1, CCNB1, SATB2, CA9, HMGB2, MB, NQO1, AURKB, and CCNB2) that demonstrates high diagnostic accuracy. Notably, TOP2A was identified as the most influential gene within this set. Additionally, spatial transcriptomics confirmed that all ten signature genes are significantly overexpressed in tumor tissues compared to adjacent normal tissues. Consequently, this signature serves not only as a diagnostic tool but also as a potential indicator of therapeutic response.

Molecular docking and dynamic simulations further supported these findings by revealing strong binding affinities (ΔG ≤ -8.5 kcal/mol) between baicalein and core proteins such as AURKB and TOP2A. Moreover, in vitro experiments showed that baicalein suppresses cancer cell viability in a dose- and time-dependent manner. Cell-cell communication analysis also highlighted the MIF pathway's role, with epithelial cells and specific macrophages acting as key signaling mediators in the TME.

Conclusion

This integrative research provides a comprehensive understanding of how baicalein might be utilized as a therapeutic agent. By identifying a specific 10-gene signature, the study bridges the gap between traditional herbal pharmacology and modern precision medicine. Therefore, these insights offer a foundation for developing baicalein as a potential clinical intervention for patients with NSCLC.

Frequently Asked Questions

What is the role of TOP2A in the baicalein response signature?

TOP2A was identified through SHAP analysis as the most influential contributor to the 10-gene signature. It acts as a primary target for baicalein, and its high expression in tumor tissues makes it a critical marker for diagnostic and therapeutic monitoring in NSCLC.

How does spatial transcriptomics improve our understanding of NSCLC?

Spatial transcriptomics allows researchers to confirm where specific genes are expressed within the actual tissue architecture. In this study, it was used to prove that the 10-gene signature identified for baicalein response is specifically elevated within the tumor areas rather than healthy lung tissue.

Is baicalein currently used in standard NSCLC treatment?

While baicalein shows significant anti-cancer activity in preclinical models and transcriptomic studies, it is currently considered a potential therapeutic agent rather than a first-line standard treatment. It is often studied within the context of integrative oncology and complementary medicine.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.

References

Wu D et al. Integrative single-cell and spatial transcriptomics analysis reveals a baicalein-responsive 10-gene signature for non-small cell lung cancer. Transl Oncol. 2026 Jun 07. doi: undefined. PMID: 42251782.

Zhang X et al. Baicalein inhibits non-small-cell lung cancer invasion and metastasis by reducing ezrin tension in inflammation microenvironment. Cancer Sci. 2020 Oct;111(10):3802-3812.

Li P et al. Baicalein is a potential agent targeting glutamine that induces apoptosis by inhibiting the glutamine-mTOR metabolic pathway in lung cancer. Transl Oncol. 2024.